The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan

被引:21
作者
Mulford, Darcy J. [1 ]
Leifke, Eckhard [1 ]
Hibberd, Mark [1 ]
Howden, Colin W. [2 ]
机构
[1] Phathom Pharmaceut, Res & Dev, Buffalo Grove, IL USA
[2] Univ Tennessee, Ctr Hlth Sci, Div Gastroenterol, Memphis, TN 38163 USA
来源
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT | 2022年 / 11卷 / 02期
关键词
food effect; metabolites; pharmacodynamics; pharmacokinetics; vonoprazan; ESOMEPRAZOLE; TAK-438; LANSOPRAZOLE; EFFICACY; TRIAL;
D O I
10.1002/cpdd.1009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Herein, we report a food-effect study of vonoprazan, an oral potassium-competitive acid blocker. In a phase 1, randomized, open-label, crossover study, healthy subjects received a single 20-mg dose of vonoprazan either following an overnight fast or 30 minutes after a high-fat breakfast. Plasma vonoprazan levels were determined at 0 hour and at 17 subsequent assessment points up to 48 hours after dosing. After a 5-day washout, subjects received a second 20-mg vonoprazan dose in the alternative fed/fasted state (identical process repeated). Twenty-four subjects completed the study. Vonoprazan exposure was not meaningfully affected by food. Geometric mean ratios for maximum concentration, area under the concentration-time curve from time 0 to 24 hours, and area under the plasma concentration-time curve extrapolated to infinity obtained under fed and fasting conditions were 1.05 (90% confidence interval, 0.98-1.12), 1.13 (1.09-1.18), and 1.15 (1.11-1.19), respectively. Four subjects experienced 6 adverse events that were all mild and considered unrelated to the study drug. Vonoprazan can be administered without regard to food intake.
引用
收藏
页码:278 / 284
页数:7
相关论文
共 29 条
  • [1] Discovery of a Novel Pyrrole Derivative 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Fumarate (TAK-438) as a Potassium-Competitive Acid Blocker (P-CAB)
    Arikawa, Yasuyoshi
    Nishida, Haruyulci
    Kurasawa, Osamu
    Hasuoka, Atsushi
    Hirase, Keizo
    Inatomi, Nobuhiro
    Hori, Yasunobu
    Matsukawa, Jun
    Imanishi, Akio
    Kondo, Mitsuyo
    Tarui, Naoki
    Hamada, Teruki
    Takagi, Terufumi
    Takeuchi, Toshiyuki
    Kajino, Masahiro
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (09) : 4446 - 4456
  • [2] Effect of Therapeutic and Supratherapeutic Doses of Vonoprazan on the QT/QTc Interval in a Phase I Randomized Study in Healthy Subjects
    Astruc, B.
    Jenkins, H.
    Jenkins, R.
    [J]. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2017, 10 (03): : 208 - 216
  • [3] Early Stellate Cell Activation and Veno-occlusive-disease (VOD)-like Hepatotoxicity in Dogs Treated with AR-H047108, an Imidazopyridine Proton Pump Inhibitor
    Berg, Anna-Lena
    Bottcher, Gerhard
    Andersson, Kjell
    Carlsson, Enar
    Lindstrom, Anna-Karin
    Huby, Russell
    Hakansson, Helen
    Skanberg-Wilhelmsson, Inger
    Hellmold, Heike
    [J]. TOXICOLOGIC PATHOLOGY, 2008, 36 (05) : 727 - 737
  • [4] A Randomized, Comparative Trial of a Potassium-Competitive Acid blocker (AZD0865)and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
    Dent, John
    Kahrilas, Peter J.
    Hatlebakk, Jan
    Vakil, Nimish
    Denison, Hans
    Franzen, Stefan
    Lundborg, Per
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (01) : 20 - 26
  • [5] The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations
    Echizen, Hirotoshi
    [J]. CLINICAL PHARMACOKINETICS, 2016, 55 (04) : 409 - 418
  • [6] Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis
    Fennerty, MB
    Johanson, JF
    Hwang, C
    Sostek, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (04) : 455 - 463
  • [7] Furuta Takahisa, 2005, Drug Metab Pharmacokinet, V20, P153, DOI 10.2133/dmpk.20.153
  • [8] The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017
    Dirac M.A.
    Safiri S.
    Tsoi D.
    Adedoyin R.A.
    Afshin A.
    Akhlaghi N.
    Alahdab F.
    Almulhim A.M.
    Amini S.
    Ausloos F.
    Bacha U.
    Banach M.
    Bhagavathula A.S.
    Bijani A.
    Biondi A.
    Borzì A.M.
    Colombara D.
    Dagnew B.
    Daryani A.
    Davitoiu D.V.
    Demeke F.M.
    Demoz G.T.
    Do H.P.
    Etemadi A.
    Farzadfar F.
    Fischer F.
    Gebre A.K.
    Gebremariam H.
    Gebremichael B.
    Ghashghaee A.
    Ghoshal U.C.
    Hamidi S.
    Hasankhani M.
    Hassan S.
    Hay S.I.
    Hoang C.L.
    Hole M.K.
    Ikuta K.S.
    Ilesanmi O.S.
    Irvani S.S.N.
    James S.L.
    Joukar F.
    Kabir A.
    Kassaye H.G.
    Kavetskyy T.
    Kengne A.P.
    Khalilov R.
    Khan M.U.
    Khan E.A.
    Khan M.
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2020, 5 (06): : 561 - 581
  • [9] Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease
    Gunaratnam, NT
    Jessup, TP
    Inadomi, J
    Lascewski, DP
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (10) : 1473 - 1477
  • [10] Proton pump inhibitors: better acid suppression when taken before a meal than without a meal
    Hatlebakk, JG
    Katz, PO
    Camacho-Lobato, L
    Castell, DO
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2000, 14 (10) : 1267 - 1272